Phase 4
N=19
Liposomal Bupivacaine (Exparel) for Postoperative Pain Control for Open and Laparoscopic Abdominal Hernia Repair
Pain
Bottom Line
View on ClinicalTrials.gov: NCT02128646 ↗Enrolled (actual)
19
Serious AEs
0.0%
Results posted
Sep 2025
Primary outcome: Primary: Patient Satisfaction With Pain Management After Surgery — 4; 4; 2.5; 5 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- EXPAREL (Drug); Ketorolac (Drug); laparoscopic abdominal hernia repair (Procedure); an open surgery for abdominal hernia repair (Procedure)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Kansas Medical Center
- Primary completion
- Jan 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Patient Satisfaction With Pain Management After Surgery |
4; 4; 2.5; 5 | — |
| SECONDARY Total Length of Time in Post-anesthesia Care Unit (PACU) |
93.5; 64; 118; 86 | — |
Summary
The purpose of this study is to learn how well Liposomal Bupivacaine (Exparel™) controls post-operative pain in patients undergoing both open and laparoscopic (minimally invasive) abdominal hernia repair surgery.
Eligibility Criteria
Inclusion Criteria
- Patients scheduled to undergo an open or laparoscopic abdominal hernia repair.
- Ability to provide informed consent, adhere to study visit schedule, and complete all study assessments.
Exclusion Criteria
- Patients with a history of hypersensitivity or idiosyncratic reactions or intolerance to any local anesthetic, opioids or ketorolac.
- Patients who abuse alcohol or other drug substance.
- Patients who are on chronic opioid therapy (taken an opioid 5 of the last 7 days).
- Patients with severe hepatic impairment.
- Patients currently pregnant.
Data sourced from ClinicalTrials.gov (NCT02128646). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.